Starpharma today announced it has received US$3 million (A$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP^® Bcl2/xL conjugate) in December.

In this issue: 

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^® gemcitabine

>> GMP DEP^® facility licence

>> DEP^® combinations add further value

>> Outlook, recent news & events

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2019.

Starpharma today announced that AstraZeneca (LSE/STO/NYSE: AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP^® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers and will be conducted at 4-5 US sites.

Starpharma today announced that it has received a $4.9M R&D tax incentive refund which relates to the costs of research and development during the 2019 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including DEP^® and VivaGel^®.

Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP^® cabazitaxel. The trial met its objective of evaluating safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose of 20 mg/m². The trial will now transition seamlessly into phase 2, with two new sites initiated and recruitment activities already underway.

Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 4.00pm today.

Starpharma today announced that it has been granted marketing approval for the VivaGel^® condom in Europe.  

Starpharma today notifies that its 2019 AGM will be held at 4pm on 21 November 2019 at RACV City Club, Level 2, 501 Bourke Street, Melbourne, Victoria.

The AGM will be recorded and available via webcast later that day. To access the webcast, participants can register via the following link:

https://webcasting.boardroom.media/broadcast/5dccc1f06242591605116cb6

Starpharma today announced that VivaGel^® BV has been launched in the UK under the brand Betafem^® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.